This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Empliciti
  • /
  • Phase III Study of Lenalidomide and Dexamethasone ...
Clinical trial

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)

Read time: 1 mins
Last updated:31st May 2021
Status: COMPLETED
Identifier: NCT01239797
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2)


ClinicalTrials.gov ID: NCT01239797
Sponsor: Bristol-Myers Squibb
Information provided by: Bristol-Myers Squibb (Responsible Party)
Last Update Posted: 2022-06-01

Brief Summary:
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).

Official Title:
Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)

Intervention / Treatment:
- Drug: Lenalidomide
- Drug: Dexamethasone
- Drug: Dexamethasone (Oral)
- Drug: Dexamethasone (IV)
- Biological: Elotuzumab (BMS-901608; HuLuc63)

Category Value
Study Start (Actual)
2011-06-20
Primary Completion (Actual)
2014-09-02
Study Completion (Actual)
2021-04-21
Enrollment (Actual) 646
Study Type Interventional
Phase Phase 3
Other Study ID Numbers
CA204-004

2010-020347-12 (EudraCT Number)


View full details